12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Company News  |  Deals

Debiopharm, Chugai deal

Chugai granted Debiopharm exclusive, worldwide rights to develop and commercialize FF284 ( Debio 1347), an oral small molecule against an undisclosed target in...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >